{"id":479030,"date":"2021-04-20T16:03:31","date_gmt":"2021-04-20T20:03:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/"},"modified":"2021-04-20T16:03:31","modified_gmt":"2021-04-20T20:03:31","slug":"hikma-resumes-launch-of-generic-advair-diskus","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/","title":{"rendered":"Hikma resumes launch of generic Advair Diskus\u00ae"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">LONDON<\/span>, <span class=\"xn-chron\">April 20, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Hikma Pharmaceuticals PLC\u00a0(Hikma),\u00a0the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline&#8217;s Advair Diskus<sup>\u00ae1<\/sup> in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in <span class=\"xn-chron\">January 2021<\/span>. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.\u00a0<\/p>\n<p>Hikma will immediately resume launch activities of its generic product for Advair Diskus<sup>\u00ae<\/sup> (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg\/50mcg and 250mcg\/50mcg doses in the US.<\/p>\n<p>\n        <span class=\"xn-person\">Siggi Olafsson<\/span>, Chief Executive Officer of Hikma, said: &#8220;We appreciate the FDA&#8217;s timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus<sup>\u00ae<\/sup>. We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US.&#8221; <\/p>\n<p>\n        <b>Enquiries<\/b>\n      <\/p>\n<p>\n        <b>H<\/b><br \/>\n        <b>ikma Pharmaceuticals PLC\u00a0\u00a0\u00a0 <\/b>\n      <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Susan Ringdal<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">EVP, Strategic Planning and Global Affairs<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+44 (0)20 7399 2760\/ +44 7776 477050<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:uk-investors@hikma.uk.com\" class=\"prnews_a\" rel=\"nofollow noopener\">uk-investors@hikma.uk.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Steve Weiss<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">David Belian<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">US Communications and Public Affairs\u00a0 <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+1 732 720 2830\/ +1 732 788 8279<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+1 732 720 2814\/+1 848 254 4875<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:sweiss@hikma.com\" class=\"prnews_a\" rel=\"nofollow noopener\">uscommunications@hikma.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b>Teneo (Press): \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/b>\n      <\/p>\n<div>\n<table id=\"convertedTable9d0c\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Charles Armitstead \/ Claire Scicluna<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+44 (0)7703 330 269\/+44 (0)7835 395 028<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b>About Hikma<br \/><\/b>(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-\/stable S&amp;P, BBB-\/stable Fitch and Ba1\/stable Moody&#8217;s)<\/p>\n<p>Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we&#8217;ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across <span class=\"xn-location\">the United States<\/span> (US), the <span class=\"xn-location\">Middle East<\/span> and <span class=\"xn-location\">North Africa<\/span> (MENA) and <span class=\"xn-location\">Europe<\/span>, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people&#8217;s lives. We&#8217;re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3135907-1&amp;h=2310786683&amp;u=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D2531421-1%2526h%253D3823969217%2526u%253Dhttp%25253A%25252F%25252Fwww.hikma.com%25252F%2526a%253Dwww.hikma.com%26data%3D02%257C01%257Csweiss%2540Hikma.com%257C4a35048c8c764c63c86308d70efbac9e%257C178c1a723d3c40afbaa754615303bcdc%257C0%257C1%257C636994346427346162%26sdata%3DlHZaoOb0u30Y6re6yfLW1Ar4vvBS%252FnjEUNdB00TBaTI%253D%26reserved%3D0&amp;a=www.hikma.com\" rel=\"nofollow noopener\">www.hikma.com<\/a><\/p>\n<p>\n        <sup>1\u00a0<\/sup>Advair<sup>\u00ae<\/sup> and Advair Diskus<sup>\u00ae<\/sup> are registered trademarks of GSK group of companies.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/hikma-resumes-launch-of-generic-advair-diskus-301273105.html\">http:\/\/www.prnewswire.com\/news-releases\/hikma-resumes-launch-of-generic-advair-diskus-301273105.html<\/a><\/p>\n<p>SOURCE  Hikma Pharmaceuticals <span class=\"xn-location\">USA<\/span> Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY49654&amp;Transmission_Id=202104201600PR_NEWS_USPR_____NY49654&amp;DateId=20210420\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire LONDON, April 20, 2021 \/PRNewswire\/ &#8212;\u00a0Hikma Pharmaceuticals PLC\u00a0(Hikma),\u00a0the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline&#8217;s Advair Diskus\u00ae1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.\u00a0 Hikma will immediately resume launch activities of its generic product for Advair Diskus\u00ae (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg\/50mcg and 250mcg\/50mcg doses in the US. Siggi Olafsson, Chief Executive Officer of Hikma, said: &#8220;We appreciate the FDA&#8217;s timely review and approval of our amendment and are now immediately resuming the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hikma resumes launch of generic Advair Diskus\u00ae&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479030","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hikma resumes launch of generic Advair Diskus\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hikma resumes launch of generic Advair Diskus\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LONDON, April 20, 2021 \/PRNewswire\/ &#8212;\u00a0Hikma Pharmaceuticals PLC\u00a0(Hikma),\u00a0the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline&#8217;s Advair Diskus\u00ae1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.\u00a0 Hikma will immediately resume launch activities of its generic product for Advair Diskus\u00ae (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg\/50mcg and 250mcg\/50mcg doses in the US. Siggi Olafsson, Chief Executive Officer of Hikma, said: &#8220;We appreciate the FDA&#8217;s timely review and approval of our amendment and are now immediately resuming the &hellip; Continue reading &quot;Hikma resumes launch of generic Advair Diskus\u00ae&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-20T20:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hikma resumes launch of generic Advair Diskus\u00ae\",\"datePublished\":\"2021-04-20T20:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/\"},\"wordCount\":405,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY49654&amp;sd=2021-04-20\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/\",\"name\":\"Hikma resumes launch of generic Advair Diskus\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY49654&amp;sd=2021-04-20\",\"datePublished\":\"2021-04-20T20:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY49654&amp;sd=2021-04-20\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY49654&amp;sd=2021-04-20\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hikma-resumes-launch-of-generic-advair-diskus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hikma resumes launch of generic Advair Diskus\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hikma resumes launch of generic Advair Diskus\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/","og_locale":"en_US","og_type":"article","og_title":"Hikma resumes launch of generic Advair Diskus\u00ae - Market Newsdesk","og_description":"PR Newswire LONDON, April 20, 2021 \/PRNewswire\/ &#8212;\u00a0Hikma Pharmaceuticals PLC\u00a0(Hikma),\u00a0the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline&#8217;s Advair Diskus\u00ae1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.\u00a0 Hikma will immediately resume launch activities of its generic product for Advair Diskus\u00ae (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg\/50mcg and 250mcg\/50mcg doses in the US. Siggi Olafsson, Chief Executive Officer of Hikma, said: &#8220;We appreciate the FDA&#8217;s timely review and approval of our amendment and are now immediately resuming the &hellip; Continue reading \"Hikma resumes launch of generic Advair Diskus\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-20T20:03:31+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hikma resumes launch of generic Advair Diskus\u00ae","datePublished":"2021-04-20T20:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/"},"wordCount":405,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/","name":"Hikma resumes launch of generic Advair Diskus\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20","datePublished":"2021-04-20T20:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY49654&amp;sd=2021-04-20"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-resumes-launch-of-generic-advair-diskus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hikma resumes launch of generic Advair Diskus\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479030"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479030\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}